Video

Dr. Rimel on the Importance of BRCA and HRD Testing in Ovarian Cancer

Author(s):

Bobbie J. Rimel, MD

In Partnership With:

Bobbie J. Rimel, MD, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.

Bobbie J. Rimel, MD, an assistant professor of obstetrics and gynecology at Cedars-Sinai Medical Center, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.

It is important to test and identify patients with BRCA mutations in order to determine which type of therapy they are eligible for, as well as if cascade testing is needed, Rimel states. This offers patients’ family members the ability to also be tested for cancer screening prevention.

Additionally, HRD testing is valuable for understanding a patient's magnitude of benefit with maintenance PARP inhibitors, Rimel continues. Patients who are HRD have different projected progression-free survival outcomes than those who are HRP, Rimel adds. Accordingly, knowing their HRD status can better inform and guide patients' treatment decisions, Rimel concludes.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Aparna Parikh, MD
July 19th 2024

Rezatapopt Takes Aim at Previously Untargetable p53 Allele to Treat Advanced Solid Tumors

Karen L. Reckamp, MD, professor, medicine, medical oncology director, Lung Institute, director, Division of Medical Oncology, associate director, Clinical Research, Cedars-Sinai Medical Center
June 20th 2024

Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs

FDA
July 3rd 2024

OncLive’s June Roundup of Key FDA Approvals in Oncology

D. Ross Camidge, MD, PhD; B.J. Rimel, MD, assistant professor, obstetrics and gynecology, Cedars-Sinai, medical director, Cancer Clinical Trials Office, Cedars-Sinai Cancer Institute, health sciences associate clinical professor, Department of Obstetrics and Gynecology, University of California, Los Angeles
April 15th 2024

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

The FDA has approved a new drug application for Tepylute, a ready-to-dilute formulation to treat breast and ovarian cancers.
June 28th 2024

FDA Approves Tepylute for Breast and Ovarian Cancer Treatment

Susana Banerjee, MBBS, MA, PhD, FRCP, consultant medical oncologist, research lead, Gynaecology Unit, The Royal Marsden NHS Foundation Trust
June 21st 2024

Mirvetuximab Soravtansine Elicits Benefits in Ovarian Cancer Regardless of Dose Modifications